397 related articles for article (PubMed ID: 33545388)
1. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
Dagogo-Jack I; Moonsamy P; Gainor JF; Lennerz JK; Piotrowska Z; Lin JJ; Lennes IT; Sequist LV; Shaw AT; Goodwin K; Stevens SE; Do A; Digumarthy SR; Price K; Muzikansky A; Hata AN; Heist RS
J Thorac Oncol; 2021 May; 16(5):850-859. PubMed ID: 33545388
[TBL] [Abstract][Full Text] [Related]
2. Capmatinib in
Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
4. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
[TBL] [Abstract][Full Text] [Related]
6. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
Schuler M; Berardi R; Lim WT; de Jonge M; Bauer TM; Azaro A; Gottfried M; Han JY; Lee DH; Wollner M; Hong DS; Vogel A; Delmonte A; Akimov M; Ghebremariam S; Cui X; Nwana N; Giovannini M; Kim TM
Ann Oncol; 2020 Jun; 31(6):789-797. PubMed ID: 32240796
[TBL] [Abstract][Full Text] [Related]
7. Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
Seto T; Ohashi K; Sugawara S; Nishio M; Takeda M; Aoe K; Moizumi S; Nomura S; Tajima T; Hida T
Cancer Sci; 2021 Apr; 112(4):1556-1566. PubMed ID: 33506571
[TBL] [Abstract][Full Text] [Related]
8. Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
Felip E; Metro G; Tan DSW; Wolf J; Mark M; Boyer M; Hughes BGM; Bearz A; Moro-Sibilot D; Le X; Puente J; Massuti B; Tiedt R; Wang Y; Xu C; Mardjuadi FI; Cobo M
Lung Cancer; 2024 Jun; 192():107820. PubMed ID: 38763104
[TBL] [Abstract][Full Text] [Related]
9. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
Kanemura H; Takeda M; Shimizu S; Nakagawa K
Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
[TBL] [Abstract][Full Text] [Related]
10. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
12. Capmatinib for the treatment of non-small cell lung cancer.
Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
[No Abstract] [Full Text] [Related]
13. MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer.
Ramesh S; Cifci A; Javeri S; Minne RL; Longhurst CA; Nickel KP; Kimple RJ; Baschnagel AM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1379-1390. PubMed ID: 37979706
[TBL] [Abstract][Full Text] [Related]
14. Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.
Paik PK; Pfeiffer BM; Vioix H; Garcia A; Postma MJ
Adv Ther; 2022 Jul; 39(7):3159-3179. PubMed ID: 35543963
[TBL] [Abstract][Full Text] [Related]
15. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
Tseng LW; Chang JW; Wu CE
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
[TBL] [Abstract][Full Text] [Related]
16. Capmatinib for non-small cell lung cancer.
Alzofon N; Jimeno A
Drugs Today (Barc); 2021 Jan; 57(1):17-25. PubMed ID: 33594387
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
18. Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy.
Zuckermann M; He C; Andrews J; Bagchi A; Sloan-Henry R; Bianski B; Xie J; Wang Y; Twarog N; Onar-Thomas A; Ernst KJ; Yang L; Li Y; Zhu X; Ocasio JK; Budd KM; Dalton J; Li X; Chepyala D; Zhang J; Xu K; Hover L; Roach JT; Chan KC; Hofmann N; McKinnon PJ; Pfister SM; Shelat AA; Rankovic Z; Freeman BB; Chiang J; Jones DTW; Tinkle CL; Baker SJ
Mol Cancer; 2024 Jun; 23(1):123. PubMed ID: 38849845
[TBL] [Abstract][Full Text] [Related]
19. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib in
Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F
Clin Cancer Res; 2019 Dec; 25(24):7312-7319. PubMed ID: 31416808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
